Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 8/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.56 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.54 |
| ▸ | ULK1 | O75385 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048240 | 0.91 | ZAP70 (0.67) | ZAP70MAPK10MAPK9 | |
| SCHEMBL1049000 | 0.85 | ZAP70 (0.73) | ZAP70PTK2IGF1R | |
| SCHEMBL1049400 | 0.84 | ZAP70 (0.70) | ZAP70MAPK10IGF1RULK1 | |
| SCHEMBL1047387 | 0.82 | ZAP70 (0.77) | ZAP70 | |
| SCHEMBL1047730 | 0.82 | ZAP70 (0.67) | ZAP70MAPK10IGF1R | |
| SCHEMBL1047728 | 0.82 | ZAP70 (0.69) | ZAP70PTK2INSRIGF1RPTK2B | |
| SCHEMBL1044892 | 0.82 | ZAP70 (0.69) | ZAP70IGF1R | |
| SCHEMBL12928944 | 0.81 | ZAP70 (0.64) | ZAP70MAPK10IGF1R | |
| SCHEMBL1158385 | 0.81 | ZAP70 (0.68) | ZAP70MAPK10IGF1R | |
| SCHEMBL1045837 | 0.81 | ZAP70 (0.67) | ZAP70IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| CN-101990539-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-03-23 | — | — | CN | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| CN-101990539-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-03-23 | — | — | CN | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2238137-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885MAPK10 279/4885PTK2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.